Compare DNUT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | PRTA |
|---|---|---|
| Founded | 1937 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 539.9M |
| IPO Year | 2021 | 2013 |
| Metric | DNUT | PRTA |
|---|---|---|
| Price | $3.67 | $11.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $4.15 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.9M | 355.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,522,616,000.00 | $814,000.00 |
| Revenue This Year | $0.55 | $1,111.38 |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.58 | $4.32 |
| 52 Week High | $5.73 | $11.69 |
| Indicator | DNUT | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 60.59 |
| Support Level | $3.09 | $10.27 |
| Resistance Level | $3.87 | $11.61 |
| Average True Range (ATR) | 0.24 | 0.40 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 13.61 | 67.95 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.